ArticleInternational journal of biological macromolecules2025
Mycobacterial phthiocerol dimycocerosate induces Galectin-3 upregulation to impair proinflammatory responses and favor immune evasion.
Article in International journal of biological macromolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breaking the barrier: from biosynthetic inhibition to multidimensional modulation of the mycobacterial cell wall in tuberculosis therapy.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Mycobacterium tuberculosis, a typical intracellular parasite that causes tuberculosis, is ranked as the top infectious killer for humans in annual WHO reports. Pathogenic mycobacterium has evolved numerous strategies to favor their intracellular survival including a unique lipid-rich-cell-wall and granuloma formation during infection. Phthiocerol dimycocerosate (PDIM) is a critical virulence factor of mycobacteria including Mycobacterium marinum (Mm), which manipulate host immune responses and granuloma induction and facilitate immune evasion, but the mechanisms still remain unclear. We used an AACT/SILAC-based-quantitative proteomic approach to determine PDIM-responsive proteomics during Mm-infection. A major difference was the high abundance of Gal-3 in WT_Mm-infected cells not observed in PDIM-deficient infections. Gal-3 induction by PDIM-replete bacteria was primarily via Toll-like-receptor 2, and also engaged TGF-β non-classical-pathway. Elevated Gal-3 in macrophages prevented the turnover and translocation of NF-κB to effectively modulate the profile of inflammatory cytokines. Gal-3 Silencing effectively reduced tissue damage induced in mice by PDIM-expressing Mm. We found upregulated Gal-3 in the serum and BALF of clinical tuberculosis cases, which decreased significantly after effective chemotherapy. Our findings demonstrated that upregulated Gal-3 not only plays an important role in regulating host immune response and granuloma formation, but also suggests that targeting-Gal-3 therapy could be a promising anti-tuberculosis strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.